MOST NOTEWORTHY: Cougar Biotech, Penford and AtriaCure were today's noteworthy initiations:
- Oppenheimer believes Cougar Biotech's (NASDAQ: CGRB) lead compound abiraterone is well positioned to address two underserved lines of therapy in prostate cancer with highly unmet medical needs. The firm assumed coverage of Cougar with a Buy rating and $43 target.
- Jefferies believes Penford's (NASDAQ: PENX) initiatives to improve product mix and increase returns on capital should lift the company's valuation multiples, starting shares with a Buy rating and $33 target.
- AtriaCure (NASDAQ: ATRC) was initiated with an Outperform rating and $17 target at Barrington, as they have confidence the company's minimally invasive approach will be the standard of care procedure for the less invasive surgical management of atrial fibrillation.
OTHER INITIATIONS: